|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM334503647 |
| 003 |
DE-627 |
| 005 |
20250302192219.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202107946
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1114.xml
|
| 035 |
|
|
|a (DE-627)NLM334503647
|
| 035 |
|
|
|a (NLM)34914144
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Huang, Shiqi
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Recent Advances in Delivery Systems for Genetic and Other Novel Vaccines
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 21.11.2022
|
| 500 |
|
|
|a Date Revised 21.11.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2022 Wiley-VCH GmbH.
|
| 520 |
|
|
|a Vaccination is one of the most successful and cost-effective prophylactic measures against diseases, especially infectious diseases including smallpox and polio. However, the development of effective prophylactic or therapeutic vaccines for other diseases such as cancer remains challenging. This is often due to the imprecise control of vaccine activity in vivo which leads to insufficient/inappropriate immune responses or short immune memory. The development of new vaccine types in recent decades has created the potential for improving the protective potency against these diseases. Genetic and subunit vaccines are two major categories of these emerging vaccines. Owing to their nature, they rely heavily on delivery systems with various functions, such as effective cargo protection, immunogenicity enhancement, targeted delivery, sustained release of antigens, selective activation of humoral and/or cellular immune responses against specific antigens, and reduced adverse effects. Therefore, vaccine delivery systems may significantly affect the final outcome of genetic and other novel vaccines and are vital for their development. This review introduces these studies based on their research emphasis on functional design or administration route optimization, presents recent progress, and discusses features of new vaccine delivery systems, providing an overview of this field
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a administration routes
|
| 650 |
|
4 |
|a delivery systems
|
| 650 |
|
4 |
|a immune response
|
| 650 |
|
4 |
|a vaccines
|
| 650 |
|
7 |
|a Vaccines
|2 NLM
|
| 650 |
|
7 |
|a Antigens
|2 NLM
|
| 700 |
1 |
|
|a Zhu, Yining
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Ling
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Zhirong
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 34(2022), 46 vom: 27. Nov., Seite e2107946
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnas
|
| 773 |
1 |
8 |
|g volume:34
|g year:2022
|g number:46
|g day:27
|g month:11
|g pages:e2107946
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202107946
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 34
|j 2022
|e 46
|b 27
|c 11
|h e2107946
|